403 related articles for article (PubMed ID: 32950590)
41. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
42. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
Vuoristo M; Färkkilä M; Karvonen AL; Leino R; Lehtola J; Mäkinen J; Mattila J; Friman C; Seppälä K; Tuominen J
Gastroenterology; 1995 May; 108(5):1470-8. PubMed ID: 7729640
[TBL] [Abstract][Full Text] [Related]
43. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM; Shiffman ML; Gulamhusein A; Kowdley KV; Vierling JM; Levy C; Kremer AE; Zigmond E; Andreone P; Gordon SC; Bowlus CL; Lawitz EJ; Aspinall RJ; Pratt DS; Raikhelson K; Gonzalez-Huezo MS; Heneghan MA; Jeong SH; Ladrón de Guevara AL; Mayo MJ; Dalekos GN; Drenth JPH; Janczewska E; Leggett BA; Nevens F; Vargas V; Zuckerman E; Corpechot C; Fassio E; Hinrichsen H; Invernizzi P; Trivedi PJ; Forman L; Jones DEJ; Ryder SD; Swain MG; Steinberg A; Boudes PF; Choi YJ; McWherter CA;
Hepatology; 2023 Aug; 78(2):397-415. PubMed ID: 37386786
[TBL] [Abstract][Full Text] [Related]
44. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
45. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
47. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
[TBL] [Abstract][Full Text] [Related]
48. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.
Angulo P; Lindor KD; Therneau TM; Jorgensen RA; Malinchoc M; Kamath PS; Dickson ER
Liver; 1999 Apr; 19(2):115-21. PubMed ID: 10220741
[TBL] [Abstract][Full Text] [Related]
49. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.
Yang C; Guo G; Li B; Zheng L; Sun R; Wang X; Deng J; Jia G; Zhou X; Cui L; Guo C; Zhou X; Leung PSC; Gershwin ME; Shang Y; Han Y
Hepatol Int; 2023 Feb; 17(1):237-248. PubMed ID: 36309918
[TBL] [Abstract][Full Text] [Related]
50. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
51. A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score.
Cançado GGL; Gomes NMF; Couto CA; Cançado ELR; Terrabuio DRB; Villela-Nogueira CA; Braga MH; Nardelli MJ; Faria LC; Oliveira EMG; Rotman V; Oliveira MB; Cunha SMCFD; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; Borges VFAE; Pace FHL; Pessôa MG; Signorelli IV; Coral GP; Bittencourt PL; Fucuta P; Filho RJC; Ferraz MLG
Eur J Gastroenterol Hepatol; 2024 May; 36(5):628-635. PubMed ID: 38555601
[TBL] [Abstract][Full Text] [Related]
52. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
[TBL] [Abstract][Full Text] [Related]
53. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
[TBL] [Abstract][Full Text] [Related]
54. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
55. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C; Lemoinne S; Soret PA; Hansen B; Hirschfield G; Gulamhusein A; Montano-Loza AJ; Lytvyak E; Pares A; Olivas I; Eaton JE; Osman KT; Schramm C; Sebode M; Lohse AW; Dalekos G; Gatselis N; Nevens F; Cazzagon N; Zago A; Russo FP; Floreani A; Abbas N; Trivedi P; Thorburn D; Saffioti F; Barkai L; Roccarina D; Calvaruso V; Fichera A; Delamarre A; Sobenko N; Villamil AM; Medina-Morales E; Bonder A; Patwardhan V; Rigamonti C; Carbone M; Invernizzi P; Cristoferi L; van der Meer A; de Veer R; Zigmond E; Yehezkel E; Kremer AE; Deibel A; Bruns T; Große K; Wetten A; Dyson JK; Jones D; Dumortier J; Pageaux GP; de Lédinghen V; Chazouillères O; Carrat F;
Hepatology; 2024 Jan; 79(1):39-48. PubMed ID: 37399238
[TBL] [Abstract][Full Text] [Related]
56. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
57. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
[TBL] [Abstract][Full Text] [Related]
58. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
[TBL] [Abstract][Full Text] [Related]
59. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
60. Ursodeoxycholic acid for primary biliary cirrhosis.
Gluud C; Christensen E
Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
